|
De Novo expands operations in the USA
|
|
1st July 2005
|
Cambridge, UK and California, USA - De Novo Pharmaceuticals, the world leader in computational drug design, has announced the expansion of its USA sales and marketing office in Santa Rosa, CA, with the addition of Rachel Cranfield as Manager of US Business Development. This expansion is in response to the high level of demand for the Company’s services in the USA.
Philip Dean, CEO of De Novo, commented: “In just six months, we have signed three new drug discovery partnership deals with USA biotech companies, indicating how valuable it is for us to have a presence there. The expansion of our team in the USA, with the welcome addition of Rachel, reflects our commitment to the market as a major growth area for De Novo.”
The USA office was founded by De Novo in 2004 with the recruitment of Marc Bencivenga as VP USA Business Development. Prior to joining De Novo, Marc was the Executive Director of Business Development for Pharmacopeia, where he played a key role in establishing drug discovery partnerships for the company.
“We are extremely pleased with the level of interest we are seeing in the USA for De Novo design and specifically, for our SkelGen® platform,” said Marc Bencivenga. “There is a tremendous need for novelty and speed within the drug discovery process and this is exactly what SkelGen and the team at De Novo can provide.”
About De Novo Pharmaceuticals
De Novo Pharmaceuticals Ltd is the world leader in computational drug design. The Company provides services to drug discovery customers seeking rapid progress from validated target to novel hits, and to medicinal chemistry groups interested in focused libraries.
Using its proprietary computational software, De Novo creates novel, patentable lead molecules as candidates for drug development against both enzyme and receptor based targets. The Company’s proprietary algorithms can rapidly convert ligand information or protein structure information into new chemical designs, maximising the value within a pharmaceutical partner’s research portfolio.
De Novo was founded in 2000 and employs around 20 people in its headquarters in Cambridge, UK, and its USA office in Santa Rosa, CA. It is a venture-backed private company and its investors include Merlin Biosciences, Prelude Ventures, Life Science Partners, Avlar Bioventures, Quester Capital Management, Cambridge Gateway Fund, FNI Venture Capital, Hoffman La Roche and Incyte Capital.
|
 |
|
| |
|
Back
to news